Navidea Biopharmaceuticals (NAVB) 10-Q 12 Nov 21 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 05, 2021
Document Information [Line Items]
Entity Central Index Key	0000810509
Entity Registrant Name	NAVIDEA BIOPHARMACEUTICALS, INC.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-35076
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	31-1080091
Entity Address, Address Line One	4995 Bradenton Avenue, Suite 240
Entity Address, City or Town	Dublin
Entity Address, State or Province	OH
Entity Address, Postal Zip Code	43017-3552
City Area Code	614
Local Phone Number	793-7500
Title of 12(b) Security	Common Stock
Trading Symbol	NAVB
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		30,188,491

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 7,176,211	$ 2,670,495
Stock subscriptions and other receivables	108,323	2,987,319
Inventory	178,935	169,798
Prepaid expenses and other	193,491	700,716
Total current assets	7,656,960	6,528,328
Property and equipment	861,836	845,379
Less accumulated depreciation and amortization	735,443	713,217
Property and equipment, net	126,393	132,162
Right-of-use lease assets	458,280	458,280
Less accumulated amortization	299,641	208,185
Right-of-use lease assets, net	158,639	250,095
License agreements, patents and trademarks	947,224	747,863
Less accumulated amortization	156,862	127,622
License agreements, patents and trademarks, net	790,362	620,241
Other assets	227,192	227,192
Total assets	8,959,546	7,758,018
Current liabilities:
Accounts payable	1,206,229	1,161,717
Accrued liabilities and other	2,538,800	2,512,994
Notes payable	0	745,443
Lease liabilities, current	351,487	294,951
Total current liabilities	4,096,516	4,715,105
Lease liabilities, net of current portion	29,036	296,006
Deferred revenue	700,000	700,000
Total liabilities	4,825,552	5,711,111
Commitments and contingencies (See Note 10)
Stockholders’ equity:
Common stock; $.001 par value; 300,000,000 shares authorized; 30,163,245 and 27,149,691 shares issued and outstanding as of September 30, 2021 and December 31, 2020, respectively	221,160	218,146
Common stock subscribed; $.001 par value, 0 and 995,000 shares subscribed as of September 30, 2021 and December 31, 2020, respectively	0	995
Common stock subscriptions receivable	0	(4,975,000)
Additional paid-in capital	370,316,910	375,428,014
Accumulated deficit	(367,135,447)	(359,056,683)
Navidea stockholders' equity	3,402,695	1,315,604
Noncontrolling interest	731,299	731,303
Total stockholders’ equity	4,133,994	2,046,907
Total liabilities and stockholders’ equity	8,959,546	7,758,018
Non-Series Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	0	0
Series D Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	22	0
Preferred stock. subscriptions	0	132
Series D preferred stock subscriptions receivable	0	(10,300,000)
Series E Preferred Stock [Member]
Stockholders’ equity:
Preferred stock	$ 50	$ 0

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	300,000,000	300,000,000
Common stock, shares issued (in shares)	30,163,245	27,149,691
Common stock, shares outstanding (in shares)	30,163,245	27,149,691
Common stock subscription, shares authorized (in shares)	0	995,000
Non-Series Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Series D Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	150,000	150,000
Preferred stock, shares issued (in shares)	22,077	0
Preferred stock, shares outstanding (in shares)	22,077	0
Preferred stock subscriptions, subscribed (in shares)	0	103,000
Series E Preferred Stock [Member]
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	50,000	50,000
Preferred stock, shares outstanding (in shares)	50,000	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2021		Sep. 30, 2020		Sep. 30, 2021		Sep. 30, 2020
Revenue:
Revenue from contract with customer	$ 9,000		$ 7,000		$ 45,000		$ 31,000
Grant and other revenue	87,266		261,616		436,500		664,848
Total revenue	96,382		268,389		481,165		695,762
Cost of revenue	0		82		0		1,048
Gross profit	96,382		268,307		481,165		694,714
Operating expenses:
Research and development	1,048,786		1,377,998		3,769,596		3,659,046
Selling, general and administrative	1,469,375		1,788,934		5,132,730		4,946,279
Total operating expenses	2,518,161		3,166,932		8,902,326		8,605,325
Loss from operations	(2,421,779)	[1]	(2,898,625)	[1]	(8,421,161)	[1]	(7,910,611)
Other (expense) income:
Interest (expense) income, net	(2,814)		(149)		(4,423)		12,822
Gain on extinguishment of debt	0		0		366,000		0
Other, net	2,800		(564)		(3,141)		(777)
Total other (expense) income, net	(14)		(713)		358,436	[2]	12,045	[2]
Net loss before income taxes	(2,421,793)		(2,899,338)		(8,062,725)		(7,898,566)
Provision for income taxes	(16,043)		0		(16,043)		0
Net loss	(2,437,836)		(2,899,338)		(8,078,768)		(7,898,566)
Loss (income) attributable to noncontrolling interest	1		0		4		(1)
Deemed dividend on Series C and Series D Preferred Stock beneficial conversion feature	0		(405,555)		0		(483,333)
Net loss attributable to common stockholders	$ (2,437,835)		$ (3,304,893)		$ (8,078,764)		$ (8,381,900)
Loss attributable to common stockholders per common share (basic and diluted) (in dollars per share)	$ (0.08)		$ (0.13)		$ (0.28)		$ (0.37)
Weighted average shares outstanding (in shares)	30,122,549		25,843,732		29,067,784		22,946,201
Royalty [Member]
Revenue:
Revenue from contract with customer	$ 0		$ 2,047		$ 0		$ 26,188
License [Member]
Revenue:
Revenue from contract with customer	$ 9,116		$ 4,726		$ 44,665		$ 4,726
[1]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2]	Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]Series D Preferred Stock [Member]	Preferred Stock [Member]Series E Preferred Stock [Member]	Preferred Stock [Member]Series C Preferred Stock [Member]	Preferred Stock [Member]Private Placement [Member]	Preferred Stock [Member]Registered Direct Offering [Member]	Preferred Stock [Member]Director Fees [Member]	Preferred Stock [Member]	Preferred Stock Subscription [Member]Series D Preferred Stock [Member]	Preferred Stock Subscription [Member]Series C Preferred Stock [Member]	Preferred Stock Subscription [Member]Private Placement [Member]	Preferred Stock Subscription [Member]Registered Direct Offering [Member]	Preferred Stock Subscription [Member]Director Fees [Member]	Preferred Stock Subscription [Member]	Preferred Stock Subscriptions Receivable [Member]Series D Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member]Series C Preferred Stock [Member]	Preferred Stock Subscriptions Receivable [Member]Private Placement [Member]	Preferred Stock Subscriptions Receivable [Member]Registered Direct Offering [Member]	Preferred Stock Subscriptions Receivable [Member]Director Fees [Member]	Preferred Stock Subscriptions Receivable [Member]	Common Stock [Member]Series D Preferred Stock [Member]	Common Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]Private Placement [Member]	Common Stock [Member]Registered Direct Offering [Member]	Common Stock [Member]Director Fees [Member]	Common Stock [Member]	Common Stock Subscription [Member]Series D Preferred Stock [Member]	Common Stock Subscription [Member]Series C Preferred Stock [Member]	Common Stock Subscription [Member]Private Placement [Member]	Common Stock Subscription [Member]Registered Direct Offering [Member]	Common Stock Subscription [Member]Director Fees [Member]	Common Stock Subscription [Member]	Common Stock Subscriptions Receivable [Member]Series D Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member]Series C Preferred Stock [Member]	Common Stock Subscriptions Receivable [Member]Private Placement [Member]	Common Stock Subscriptions Receivable [Member]Director Fees [Member]	Common Stock Subscriptions Receivable [Member]	Additional Paid-in Capital [Member]Series D Preferred Stock [Member]	Additional Paid-in Capital [Member]Series E Preferred Stock [Member]	Additional Paid-in Capital [Member]Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]Private Placement [Member]	Additional Paid-in Capital [Member]Registered Direct Offering [Member]	Additional Paid-in Capital [Member]Director Fees [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]Series D Preferred Stock [Member]	Retained Earnings [Member]Series C Preferred Stock [Member]	Retained Earnings [Member]Private Placement [Member]	Retained Earnings [Member]Registered Direct Offering [Member]	Retained Earnings [Member]Director Fees [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]Series D Preferred Stock [Member]	AOCI Attributable to Parent [Member]Series C Preferred Stock [Member]	AOCI Attributable to Parent [Member]Private Placement [Member]	AOCI Attributable to Parent [Member]Registered Direct Offering [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]Series D Preferred Stock [Member]	Noncontrolling Interest [Member]Series C Preferred Stock [Member]	Noncontrolling Interest [Member]Private Placement [Member]	Noncontrolling Interest [Member]Registered Direct Offering [Member]	Noncontrolling Interest [Member]Director Fees [Member]	Noncontrolling Interest [Member]	Series D Preferred Stock [Member]	Series E Preferred Stock [Member]	Series C Preferred Stock [Member]	Private Placement [Member]	Registered Direct Offering [Member]	Director Fees [Member]	Total
Balance (in shares) at Dec. 31, 2019							0						0												19,234,960						902,162
Balance at Dec. 31, 2019							$ 0						$ 0						$ 0						$ 210,232						$ 902					$ 0							$ 345,847,676						$ (347,671,102)					$ 0						$ 731,303							$ (880,989)
Issued stock (in shares)					0					0	0											902,162	1,000,001						0
Issued stock										$ 0	$ 0					$ 0																									$ 699,000						$ 0						$ 0					$ 0							$ 700,000
Stock subscribed																0	$ 0					$ 0																		$ 2,015,126	549,353					$ 0	0					$ 0	0				$ 0	0						$ 1,105,000	550,000
Stock compensation expense																																											39,246						0					0						0							39,246
Net loss																															$ 0					0							0						(2,673,610)					0						2							(2,673,608)
Issued stock (in shares)					0					0	0											902,162	1,000,001						0
Series D Preferred Stock subscribed (See Note 11) (in shares)																						0	0					(2,373,529)	(647,058)
Series D Preferred Stock subscribed (See Note 11)																0	0					$ 0																		(2,015,126)	(549,353)					0	0					0	0				0	0						(1,105,000)	(550,000)
Issued stock in payment of services (in shares)							0						0
Issued stock in payment of services																																											4,797						0					0						0							4,801
Issued stock in payment of employee bonuses (in shares)													0																		0
Issued stock in payment of employee bonuses													$ 0																														64,458						0					0						0							64,511
Issued stock										$ 0	$ 0					0																									699,000						0						0					0							700,000
Stock subscribed (in shares)																						0	0					2,373,529	647,058
Total comprehensive loss							$ 0						0						0						0						$ 0					0							0						0					0						0							(2,673,608)
Total comprehensive loss							$ 0						$ 0						0						$ 0						$ 0					0							0						0					0						0							(2,673,608)
Issued stock upon conversion										$ 0	$ 0					0																									$ (699,000)						$ 0						$ 0					$ 0							$ (700,000)
Balance (in shares) at Mar. 31, 2020													0												21,194,248						3,020,587
Balance at Mar. 31, 2020													$ 0						0						$ 212,191						$ 3,021					(912,500)							349,219,656						(350,344,712)					0						731,305							(1,091,039)
Balance (in shares) at Dec. 31, 2019							0						0												19,234,960						902,162
Balance at Dec. 31, 2019							$ 0						$ 0						0						$ 210,232						$ 902					0							345,847,676						(347,671,102)					0						731,303							$ (880,989)
Issued stock to 401(k) Plan (in shares)																																																																			32,651
Issued stock to 401(k) Plan																																																																			$ 40,000
Net loss																																																																			(7,898,566)
Balance (in shares) at Sep. 30, 2020							0						148,500												26,373,908						1,000,000
Balance at Sep. 30, 2020							$ 0						$ 149						(14,150,000)						$ 217,370						$ 1,000					(5,000,000)							375,154,360						(356,053,002)					0						731,304							901,181
Balance (in shares) at Dec. 31, 2019							0						0												19,234,960						902,162
Balance at Dec. 31, 2019							$ 0						$ 0						0						$ 210,232						$ 902					0							345,847,676						(347,671,102)					0						731,303							(880,989)
Balance (in shares) at Dec. 31, 2020													132,250												27,149,691						995,000
Balance at Dec. 31, 2020													$ 132						(10,300,000)						$ 218,146						$ 995					(4,975,000)							375,428,014						(359,056,683)											731,303							2,046,907
Balance (in shares) at Mar. 31, 2020													0												21,194,248						3,020,587
Balance at Mar. 31, 2020													$ 0						0						$ 212,191						$ 3,021					(912,500)							349,219,656						(350,344,712)					0						731,305							(1,091,039)
Issued restricted stock (in shares)													0
Issued restricted stock													$ 0																														0						0					0						0							10
Issued stock to 401(k) Plan (in shares)													0																		0
Issued stock to 401(k) Plan													$ 0																														39,801						0					0						0							39,834
Issued stock (in shares)			70,000						0	0	0										0	1,911,800	647,058				0
Issued stock			$ 70				$ 70		$ 0	$ 0	$ 0		$ 0		$ 0	0	0				$ 0	$ 1,912					$ 0						$ 0						$ 699,930	0					$ 0	0					$ 0	0				$ 0	0						$ 700,000	520,030
Issued stock upon conversion (in shares)							70,000						0												410,765		0
Stock subscribed																						$ 0																		0						0						0					0							392,470
Stock compensation expense																																											34,588						0					0						0							34,588
Net loss																															$ 0					0							0						(2,325,618)					0						(1)							(2,325,619)
Issued stock (in shares)			70,000						0	0	0										0	1,911,800	647,058				0
Series D Preferred Stock subscribed (See Note 11)																						$ 0																		0						0						0					0							(392,470)
Issued stock in payment of employee bonuses (in shares)							0						0												40,844						0
Issued stock in payment of employee bonuses													$ 0																														106,970						0					0						0							107,011
Issued stock			$ 70				$ 70		$ 0	$ 0	$ 0		0		0	0	0				$ 0	1,912					$ 0						0						699,930	0					0	0					0	0				0	0						700,000	520,030
Total comprehensive loss							0						0						0						$ 0						$ 0					0							0						0					0						0							(2,325,619)
Total comprehensive loss							$ 0						$ 0						0						$ 0						$ 0					0							0						0					0						0							(2,325,619)
Issued restricted stock (in shares)													0
Issued restricted stock													$ 0																														0						0					0						0							10
Issued stock upon exercise of warrants (in shares)													0																		0
Issued stock upon exercise of warrants													$ 0
Deemed dividend on Series C Preferred Stock																											$ 0
Issued stock upon conversion (in shares)							(70,000)						0												(410,765)		0
Issued stock upon conversion			$ (70)				$ (70)		$ 0	$ 0	$ 0		$ 0		0	0	$ 0				$ 0	$ (1,912)					$ 0						0						(699,930)	0					0	0					0	0				0	0						(700,000)	(520,030)
Balance (in shares) at Jun. 30, 2020							0						0												24,547,961						461,729
Balance at Jun. 30, 2020							$ 0						$ 0						0						$ 215,545						$ 462					0							350,178,082						(352,748,108)					0						731,304							(1,622,715)
Issued restricted stock (in shares)							0						0												50,000						0
Issued restricted stock							$ 0						$ 0						0						$ 50						$ 0					0							0						0					0						0							50
Issued stock (in shares)	1,500		350,000	0				0	0	0										0	0	461,729				0	0	(461,729)
Issued stock	$ 2		$ 350	$ 0				$ 0	$ 0	$ 0				$ 0	0	0				$ 0	$ 0	$ 462				$ 0	$ 0	$ (462)				$ 0	0	$ 0			$ 132,089		3,462,828	0				$ 0	0	0				$ 0	0	0			$ 0	0	0				$ 132,091		3,463,178	0
Issued stock upon conversion (in shares)	(1,500)						(350,000)						0							56,497					1,014,311						0
Issued stock upon conversion	$ (2)						$ 350						$ 0						0	$ 56					$ (1,014)						$ 0					0	(54)						664						0					0						0							0
Stock subscribed	$ 0			$ 0				$ 149		$ 0				(14,150,000)		0				$ 0		$ 0				$ 0		$ 1,000				0		(5,000,000)			14,849,851			4,999,000				0		0				0		0			0		0				700,000			0
Stock compensation expense							0						0						0						0						0					0							62,515						0					0						0							62,515
Net loss							$ 0						$ 0						0						$ 0						$ 0					0							0						(2,899,338)					0						0							(2,899,338)
Issued stock (in shares)	1,500		350,000	0				0	0	0										0	0	461,729				0	0	(461,729)
Series D Preferred Stock subscribed (See Note 11) (in shares)	0			0				(148,500)		0										0		0				0		(1,000,000)
Series D Preferred Stock subscribed (See Note 11)	$ 0			$ 0				$ (149)		$ 0				14,150,000		0				$ 0		$ 0				$ 0		$ (1,000)				0		5,000,000			(14,849,851)			(4,999,000)				0		0				0		0			0		0				(700,000)			0
Issued stock in payment of services (in shares)							0						0												20,000						0
Issued stock in payment of services							$ 0						$ 0						0						$ 20						$ 0					0							65,380						0					0						0							65,400
Issued stock	$ 2		$ 350	$ 0				$ 0	$ 0	$ 0				0	0	0				$ 0	$ 0	$ 462				$ 0	$ 0	$ (462)				0	0	0			132,089		3,462,828	0				0	0	0				0	0	0			0	0	0				132,091		3,463,178	0
Stock subscribed (in shares)	0			0				148,500		0										0		0				0		1,000,000
Total comprehensive loss							0						0						0						0						0					0							0						0					0						0							(2,899,338)
Total comprehensive loss							$ 0						$ 0						0						$ 0						$ 0					0							0						0					0						0							(2,899,338)
Issued restricted stock (in shares)							0						0												50,000						0
Issued restricted stock							$ 0						$ 0						0						$ 50						$ 0					0							0						0					0						0							50
Deemed dividend on Series C Preferred Stock	$ 0		0					$ 0	0					0	0					$ 0	0					$ 0	0					0	0				16,667		388,889					(16,667)	(388,889)					0	0				0	0					0		0
Issued stock upon conversion (in shares)	1,500						350,000						0							(56,497)					(1,014,311)						0
Issued stock upon conversion	$ (2)		$ (350)	$ 0				$ 0	$ 0	$ 0				0	0	$ 0				$ 0	$ 0	$ (462)				$ 0	$ 0	$ 462				0	0	$ 0			(132,089)		(3,462,828)	$ 0				0	0	$ 0				$ 0	0	$ 0			0	0	$ 0				(132,091)		(3,463,178)	$ 0
Issued stock upon conversion of Series C Preferred Stock	$ 2						$ (350)						$ 0						0	$ (56)					$ 1,014						$ 0					0	54						(664)						0					0						0							0
Issued stock in payment of Series C Preferred Stock fees (in shares)			0				0		0				0								14,205				209,205		0				0
Issued stock in payment of Series C Preferred Stock fees			$ 0						$ 0						$ 0						$ 14						$ 0						$ 0						$ (14)						$ 0						$ 0					$ 0							$ 0
Issued stock pursuant to Jubilant MOU							$ 0						$ 0						0						$ 209						$ 0					0							999,791						0					0						0							1,000,000
Balance (in shares) at Sep. 30, 2020							0						148,500												26,373,908						1,000,000
Balance at Sep. 30, 2020							$ 0						$ 149						(14,150,000)						$ 217,370						$ 1,000					(5,000,000)							375,154,360						(356,053,002)					$ 0						731,304							901,181
Balance (in shares) at Dec. 31, 2020													132,250												27,149,691						995,000
Balance at Dec. 31, 2020													$ 132						(10,300,000)						$ 218,146						$ 995					(4,975,000)							375,428,014						(359,056,683)											731,303							2,046,907
Issued restricted stock (in shares)																									12,500
Issued restricted stock																									$ 13																																										13
Issued stock to 401(k) Plan (in shares)																									30,018
Issued stock to 401(k) Plan																									$ 30																		76,816																								76,846
Issued stock (in shares)	31,750	50,000						(31,750)
Issued stock	$ 32	$ 50						$ (31)						250,000																								$ 4,980,659																							250,001	$ 4,980,709
Issued stock upon conversion (in shares)	(31,750)																			1,513,978						0
Issued stock upon conversion	$ (32)																			$ 1,514																	(1,482)
Stock subscribed														500,000																																															500,000
Stock compensation expense																																											121,298																								121,298
Net loss																																																	(2,966,890)											(2)							(2,966,892)
Issued stock (in shares)	31,750	50,000						(31,750)
Series D Preferred Stock subscribed (See Note 11)														(500,000)																																															(500,000)
Issued stock	$ 32	$ 50						$ (31)						250,000																								4,980,659																							250,001	4,980,709
Issued restricted stock (in shares)																									12,500
Issued restricted stock																									$ 13																																										13
Issued stock upon conversion (in shares)	31,750																			(1,513,978)						0
Issued stock upon conversion	$ (32)	$ (50)						31						(250,000)																								$ (4,980,659)																							(250,001)	$ (4,980,709)
Issued stock upon conversion of Series C Preferred Stock	$ 32																			$ (1,514)																	1,482
Balance (in shares) at Mar. 31, 2021							50,000						100,500												28,706,187						995,000
Balance at Mar. 31, 2021																																																																			5,008,882
Balance (in shares) at Dec. 31, 2020													132,250												27,149,691						995,000
Balance at Dec. 31, 2020													$ 132						(10,300,000)						$ 218,146						$ 995					(4,975,000)							375,428,014						(359,056,683)											731,303							$ 2,046,907
Issued stock to 401(k) Plan (in shares)																																																																			30,018
Issued stock to 401(k) Plan																																																																			$ 77,000
Net loss																																																																			$ (8,078,768)
Issued stock upon stock option exercise (in shares)																																																																			2,000
Balance (in shares) at Sep. 30, 2021							72,077						0												30,163,245						0
Balance at Sep. 30, 2021							$ 72						$ 0						0						$ 221,160						$ 0					0							370,316,910						(367,135,447)											731,299							$ 4,133,994
Balance (in shares) at Mar. 31, 2021							50,000						100,500												28,706,187						995,000
Balance at Mar. 31, 2021																																																																			5,008,882
Issued stock (in shares)							23,000						(23,000)												0						0
Issued stock							$ 23						$ (23)						1,800,000						$ 0						$ 0					0							0						0											0							1,800,000
Issued stock upon conversion (in shares)							(23,000)																		1,437,531
Issued stock upon conversion							$ (23)																		$ 1,437						0												(1,414)
Stock subscribed								$ 56						(7,750,000)																	995					(4,975,000)	5,542,245						4,974,005																		(2,207,699)
Stock compensation expense																																											142,180																								142,180
Net loss							$ 0						$ 0						0						$ 0						$ 0					0							0						(2,764,039)											(1)							(2,674,040)
Issued stock (in shares)							23,000						(23,000)												0						0
Series D Preferred Stock subscribed (See Note 11) (in shares)								(55,423)																							(995,000)
Series D Preferred Stock subscribed (See Note 11)								$ (56)						7,750,000																	$ (995)					4,975,000	(5,542,245)						(4,974,005)																		2,207,699
Incurred costs related to Series E Preferred Stock																																											(50,671)																								(50,671)
Issued stock upon stock option exercise (in shares)																									2,000
Issued stock upon stock option exercise																									$ 2																		2,118																								2,120
Issued stock							$ 23						$ (23)						1,800,000						$ 0						$ 0					0							0						0											0							1,800,000
Stock subscribed (in shares)								55,423																							995,000
Issued stock upon conversion (in shares)							23,000																		(1,437,531)
Issued stock upon conversion							$ (23)						$ 23						(1,800,000)						$ 0						$ 0					0							0						0											0							(1,800,000)
Issued stock upon conversion of Series C Preferred Stock							$ 23																		$ (1,437)						$ 0												1,414
Balance (in shares) at Jun. 30, 2021							50,000						22,077												30,145,718
Balance at Jun. 30, 2021							$ 50						$ 22												$ 221,142																		370,181,268						(364,697,612)											731,300							6,436,170
Issued restricted stock (in shares)							0						0												2.500						0
Issued restricted stock							$ 0						$ 0						0						$ 3						$ 0					0							0						0											0							3
Issued stock (in shares)	22,077							(22,077)												0						0
Issued stock	$ 22							$ (22)						0						$ 0						$ 0						0					0							0											0						0
Stock compensation expense							0						0						0						0						0					0							108,157						0											0							108,157
Net loss							$ 0						$ 0						0						$ 0						$ 0					0							0						(2,437,835)											(1)							(2,437,836)
Issued stock (in shares)	22,077							(22,077)												0						0
Issued stock in lieu of cash in payment of director fees (in shares)						0						0												15.027						0
Issued stock in lieu of cash in payment of director fees						$ 0						$ 0						$ 0						$ 15						$ 0					$ 0							$ 27,485						$ 0											$ 0							$ 27,500
Issued stock	$ 22							$ (22)						0						$ 0						$ 0						0					0							0											0						0
Issued restricted stock (in shares)							0						0												2.500						0
Issued restricted stock							$ 0						$ 0						0						$ 3						$ 0					0							0						0											0							3
Issued stock upon conversion	$ (22)							$ 22						$ 0						$ 0						$ 0						$ 0					$ 0							$ 0											$ 0						$ 0
Balance (in shares) at Sep. 30, 2021							72,077						0												30,163,245						0
Balance at Sep. 30, 2021							$ 72						$ 0						$ 0						$ 221,160						$ 0					$ 0							$ 370,316,910						$ (367,135,447)											$ 731,299							$ 4,133,994

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	1 Months Ended	3 Months Ended				9 Months Ended		12 Months Ended
	Dec. 31, 2019	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities:
Net loss		$ (2,437,836)	$ (2,966,892)	$ (2,899,338)	$ (2,673,608)	$ (8,078,768)	$ (7,898,566)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization						55,672	51,501
Loss (gain) on disposal and abandonment of assets						19,962	(1,042)
Non-cash lease expense						91,456	90,002
Stock compensation expense						371,637	136,349
Gain on extinguishment of debt		0		0		(366,000)	0
Value of stock issued to 401(k) plan for employer matching contributions						76,846	39,834
Value of stock issued in lieu of cash in payment of director fees						27,500	0
Value of stock issued in payment of employee bonuses						0	171,522
Value of stock issued in payment of services						0	70,201
Changes in operating assets and liabilities:
Receivables						(46,005)	781,128
Inventory						(9,137)	0
Prepaid expenses and other assets						507,225	1,028,016
Accounts payable						44,512	3,802
Accrued and other liabilities						35,161	105,017
Lease liabilities						(210,434)	(185,339)
Deferred revenue						(9,356)	(9,355)
Net cash used in operating activities						(7,489,729)	(5,616,930)
Cash flows from investing activities:
Payments for purchases of equipment		(18,042)		(120,810)		(20,749)	(129,216)
Proceeds from sale of equipment						0	1,042
Patent and trademark costs						(219,236)	(202,078)
Net cash used in investing activities						(239,985)	(330,252)
Cash flows from financing activities:
Proceeds from issuance of preferred stock, including collection of stock subscriptions receivable						12,682,700	4,350,000
Proceeds from issuance of common stock	$ 1,900,000					2,135	4,417,560		$ 1,100,000
Proceeds from note payable						0	366,000
Principal payments on notes payable						(379,443)	(305,955)
Net cash provided by financing activities						12,235,430	8,622,875
Net increase in cash and cash equivalents						4,505,716	2,675,693
Cash and cash equivalents, beginning of period			$ 2,670,495		$ 1,047,159	2,670,495	1,047,159	$ 1,047,159
Cash and cash equivalents, end of period	$ 1,047,159	$ 7,176,211		$ 3,722,852		7,176,211	3,722,852	$ 2,670,495	$ 1,047,159
Preferred Stock Issuance Costs [Member]
Cash flows from financing activities:
Payment of stock issuance costs						(69,962)	(54,730)
Common Stock Issuance Costs [Member]
Cash flows from financing activities:
Payment of stock issuance costs						$ 0	$ (150,000)

Note 1 - Summary of Significant

Note 1 - Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Significant Accounting Policies [Text Block]	1. Summary of Significant Accounting Policies a. Basis of Presentation: September 30, 2021 three nine September 30, 2021 2020 September 30, 2021 not December 31, 2020, 10 Our condensed consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Europe Limited (“Navidea Europe”) and Navidea Biopharmaceuticals Limited (“Navidea UK”), as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation. b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents, stock subscriptions and other receivables, and accounts payable: ( 2 Notes payable: September 30, 2021 December 31, 2020 September 30, 2021 December 31, 2020, 8. c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3. d. Leases: 2018. 12 not 9. e. Convertible Preferred Stock: 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 470, Debt 268, Presentation in Financial Statements of Redeemable Preferred Stocks not not No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity January 1, 2021, not not 11. f. Recently Adopted Accounting Standards: December 2019, No. 2019 12, Income Taxes (Topic 740 2019 12 2019 12 740 2019 12 December 12, 2020, 2019 12 not In August 2020, No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 2020 06 2020 06 2020 06 2020 06 December 15, 2021, December 15, 2023 2020 06 January 1, 2021 2020 06 not g. Recently Issued Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 ASU2 021 04 ASU2021 04 2021 04 December 15, 2021, not 2021 04

Note 2 - Liquidity

Note 2 - Liquidity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Substantial Doubt about Going Concern [Text Block]	2. Liquidity As disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10 10. In addition, the Company is engaged in ongoing litigation with our former President and Chief Executive Officer, Dr. Michael Goldberg. See Note 10. The Company has also been engaged in ongoing litigation with Capital Royalty Partners II L.P. (“CRG”). See Note 10. On August 30, 2020, 10 $5.0 second 2021, second 2021. 11. On August 31, 2020, one nine 3 July 8, 2021 ( 22,077 nine September 30, 2021 no September 30, 2021. 10 not 11. On March 2, 2021, 10 none 11. The Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted on March 27, 2020. 7 May 18, 2020, February 23, 2021, 8. We do not 19 19 NAV3 32 19 19 The Company has experienced recurring net losses and has used significant cash to fund its operations. The Company has considerable discretion over the extent of development project expenditures and has the ability to curtail the related cash flows as needed. The Company also has funds remaining under outstanding grant awards, and continues working to establish new sources of funding, including collaborations, potential equity investments, and additional grant funding that can augment the balance sheet. However, based on our current working capital and our projected cash burn, management believes that there is substantial doubt about the Company’s ability to continue as a going concern for a period of one 10 No

Note 3 - Revenue From Contracts

Note 3 - Revenue From Contracts With Customers	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	3. Revenue from Contracts with Customers Navidea is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. We manage our business based on two Tc99m Tc99m one Tc99 not May 11, 2020, The Company also has an agreement in place to provide Meilleur Technologies, Inc., (“Meilleur”), a wholly-owned subsidiary of Cerveau Technologies, Inc. (“Cerveau”), worldwide rights to conduct research using NAV4694, NAV4694 Currently, the Company recognizes revenue from up-front license fees and pre-market milestones after the cash has been received from its customers and the performance obligations have been met. Payments for sales-based royalties and milestones are generally received after the related revenue has been recognized and invoiced. Normal payment terms generally range from 15 to 90 days following milestone achievement or royalty invoice, in accordance with each contract. Up-front and milestone payments received related to our license and distribution agreements in India and China are deferred until Tc99m not Tc99m not no not eight ten The transaction price of a contract is the amount of consideration to which the Company expects to be entitled in exchange for transferring promised goods or services to a customer. Transaction prices do not third not When estimating a contract’s transaction price, the Company considers all the information (historical, current, and forecasted) that is reasonably available to it and identifies possible consideration amounts. Most of the Company’s contracts with customers include both fixed and variable components of the transaction price. Under those contracts, some or all of the consideration for satisfied performance obligations is contingent on events over which the Company has no Tc99m The milestone payments have a binary outcome (that is, the Company will either receive all or none not Royalties are estimated based on the expected value method because they are based on a variable amount of sales representing a range of possible outcomes. However, when taking into account the constraint on variable consideration, the estimate of future royalties included in the transaction price is generally $0. This conclusion is based on the fact that Tc99m not no no The sublicense of NAV4694 No. 606, Revenue from Contracts with Customers 606” Up-front fees, milestones and royalties are generally non-refundable. Therefore, the Company does not During the three September 30, 2021 2020, nine September 30, 2021 2020, three nine September 30, 2021 2020, not The following table disaggregates the Company’s revenue from contracts with customers for the three nine September 30, 2021 2020. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Royalty revenue: Tc99m tilmanocept - Europe $ — $ 2,047 $ — $ 26,188 License revenue: Tc99m tilmanocept - Europe $ 9,116 $ 4,726 $ 44,665 $ 4,726 The following economic factors affect the nature, amount, timing and uncertainty of the Company’s revenue and cash flows as indicated: Geographical Location of Customers: may may Tc99m Status of Regulatory Approval: Tc99m Tc99m Tc99m not may NAV4694 not Through September 30, 2021, not The following table summarizes the changes in contract liabilities, the current portion of which is included in accrued liabilities and other in the condensed consolidated balance sheets, during the three nine September 30, 2021 2020. Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Total deferred revenue, beginning of period $ 700,000 $ 860,000 $ 700,000 $ 700,000 Revenue deferred related to sublicense — — — 160,000 Refund of deferred revenue related to sublicense — (160,000 ) — (160,000 ) Revenue recognized from satisfaction of performance obligations — — — — Total deferred revenue, end of period $ 700,000 $ 700,000 $ 700,000 $ 700,000 The Company had license revenue receivable of approximately $107,000 and $59,000 outstanding as of September 30, 2021 December 31, 2020. In addition to revenue from contracts from customers, we also generate revenue from National Institutes of Health (“NIH”) grants to support various product development initiatives. The revenue recognition standard applies to revenue from contracts with customers. A customer is defined as a party that has contracted with an entity to obtain goods or services that are an output of the entity’s ongoing major or central operations in exchange for consideration. The Company’s ongoing major or central operations consist of the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The NIH and its various institutes are responsible for biomedical and public health research and provide major biomedical research funding to non-NIH research facilities and entities such as Navidea. While the Company will directly benefit from any knowledge gained from the project, there is also a public health benefit provided, which justifies the use of public funds in the form of the grants. Based on the nature of the Company’s operations and the terms of the grant awards, Navidea does not not three September 30, 2021 2020, nine September 30, 2021 2020, On May 11, 2020 ( March 5, 2015 ( Tc99m Pursuant to the Termination Agreement, the parties agreed that neither owed the other any payments due under the License Agreement as of the Termination Date and that, among other things, SpePharm no six ninety fourth 2021.

Note 4 - Stock-based Compensati

Note 4 - Stock-based Compensation	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	4. Stock-Based Compensation For the three September 30, 2021 2020, nine September 30, 2021 2020, not three nine September 30, 2021 2020. A summary of the status of our stock options as of September 30, 2021, nine Nine Months Ended September 30, 2021 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding, January 1, 2021 549,970 $ 8.81 8.0 $ 209,280 Granted 234,500 2.53 Exercised (2,000 ) 1.06 Cancelled/Forfeited (67,600 ) 4.01 Expired (2,090 ) 61.75 Outstanding, September 30, 2021 712,780 $ 7.07 7.6 $ 128,765 Exercisable, September 30, 2021 222,882 $ 13.27 5.6 $ 47,381 The weighted average grant date fair value per stock option granted during the nine September 30, 2021 nine September 30, 2021 A summary of the status of our unvested restricted stock as of September 30, 2021, nine Nine Months Ended September 30, 2021 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2021 60,000 $ 2.90 Granted 15,000 2.17 Vested (36,667 ) 2.40 Unvested, September 30, 2021 38,333 $ 3.10 As of September 30, 2021,

Note 5 - Loss Per Share

Note 5 - Loss Per Share	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Earnings Per Share [Text Block]	5. Loss Per Share Basic loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares. Diluted loss per share reflects additional common shares that would have been outstanding if dilutive potential common shares had been issued. Potential common shares that may Diluted loss per common share for the nine September 30, 2021 2020 The Company’s unvested restricted stock awards contain nonforfeitable rights to dividends or dividend equivalents, whether paid or unpaid (referred to as “participating securities”). Therefore, the unvested restricted stock awards are required to be included in the number of shares outstanding for both basic and diluted earnings per share calculations. However, due to our loss from continuing operations, 38,333 and 60,000 shares of unvested restricted stock for the nine September 30, 2021 2020,

Note 6 - Inventory

Note 6 - Inventory	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Inventory Disclosure [Text Block]	6. Inventory The components of inventory as of September 30, 2021 December 31, 2020 September 30, 2021 December 31, 2020 Materials $ 77,750 $ 77,750 Finished goods 101,185 92,048 Total inventory $ 178,935 $ 169,798 During the three nine September 30, 2021,

Note 7 - Accounts Payable, Accr

Note 7 - Accounts Payable, Accrued Liabilities and Other	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	7. Accounts Payable, Accrued Liabilities and Other Accounts payable as of September 30, 2021 December 31, 2020 September 30, 2021 December 31, 2020 2021, third September 30, 2021.

Note 8 - Notes Payable

Note 8 - Notes Payable	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Debt Disclosure [Text Block]	8. Notes Payable First Insurance Funding In November 2019, eight July 2020. Interest expense related to the FIF note payable totaled $0 and $5,000 during the three nine September 30, 2020, IPFS Corporation In November 2020, seven June 2021. Interest expense related to the IPFS note payable totaled $0 and $4,000 during the three nine September 30, 2021, September 30, 2021 December 31, 2020, Paycheck Protection Program The CARES Act was enacted on March 27, 2020. May 18, 2020, February 23, 2021, 2. Summary During the three September 30, 2021 2020, nine September 30, 2021 2020,

Note 9 - Leases

Note 9 - Leases	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	9. Leases We currently lease approximately 5,000 square feet of office space at 4995 June 2023. In addition, we currently lease approximately 25,000 square feet of office space at 5600 2021. October 2022 five not June 2017, October 2022. We currently lease office equipment at a monthly payment of approximately $100, expiring in October 2024. September 2021. Total operating lease expense was $42,000 and $49,000 for the three September 30, 2021 2020, nine September 30, 2021 2020, The following table presents information about the amount, timing and uncertainty of cash flows arising from the Company’s operating leases as of September 30, 2021. Maturity of Lease Liabilities Operating Lease Payments 2021 (remaining) $ 93,889 2022 291,111 2023 19,699 2024 1,355 Total undiscounted operating lease payments 406,054 Less imputed interest 25,531 Present value of operating lease liabilities $ 380,523 Balance Sheet Classification Current lease liabilities $ 351,487 Noncurrent lease liabilities 29,036 Total operating lease liabilities $ 380,523 Other Information Weighted-average remaining lease term for operating leases (in years) 1.1 Weighted-average discount rate for operating leases 11.0 % Cash paid for amounts included in the present value of operating lease liabilities was $251,000 and $246,000 during the nine September 30, 2021 2020,

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	10. Commitments and Contingencies We are subject to legal proceedings and claims that arise in the ordinary course of business. In accordance with ASC Topic 450, Contingencies CRG Litigation As disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10 February 1, 2021. July 1, 2021. August 18, 2021, October 25, 2021, not The Company has also been engaged in ongoing litigation with CRG in the Court of Common Pleas of Franklin County, Ohio (the “Ohio Court”). On March 16, 2021, 10th not not April 30, 2021, July 20, 2021 August 5, 2021, 2. Platinum Litigation As disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10 June 28, 2021. December 8, 2021 December 17, 2021. January 2022 2. Goldberg Agreement and Litigation As disclosed in the notes to the financial statements included in the Company’s Annual Report on Form 10 August 2018, New York Litigation Involving Dr. Goldberg On February 20, 2019, April 26, 2019, June 13, 2019, third During the course of the New York litigation, the District Court issued a variety of rulings which included, inter alia third On May 27, 2021, 1 2 3 not 4 not third 5 6 not On August 6, 2021, June 23, 2021 ( October 14, 2021, Fact discovery in the New York Action has been completed and the Court has ordered that expert discovery be completed no November 30, 2021. Delaware Litigation Involving Dr. Goldberg On February 20, 2019, June 12, 2019, not May 23, 2019 On June 23, 2021, not not The parties are in the process of submitting materials in response to Navidea’s request to be reimbursed approximately $70,000 in connection with the Delaware Court’s previous finding that Dr. Goldberg was in contempt of a Court order. Once that issue is resolved, Navidea expects a final judgment to be entered. See Note 2. NYSE American Continued Listing Standards Navidea must maintain compliance with NYSE American continued listing standards, including those relating to stockholders’ equity. Specifically, Sections 1003 $6.0 five September 30, 2021, Even if an issuer does not 1003 not 1 $50,000,000; $50,000,000 two three 2 1,100,000 $15,000,000 400 September 30, 2021, September 30, 2021 $50.0 may not may

Note 11 - Equity

Note 11 - Equity	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	11. Equity In December 2019, 2019. January 2020. In February 2020, two 2020. On August 30, 2020, 10 $5.0 December 31, 2020. second 2021, second 2021. On August 31, 2020, one July 8, 2021, August 31, 2020 September 30, 2021. nine September 30, 2021 no 10 December 31, 2020. $2.925 December 31, 2020. 2. On March 2, 2021, Under the Series E Preferred Stock Purchase Agreement, Mr. Scott was granted a right of first no 33.33% 13 1934, not third not no no may December 31, 2021 In connection with the private placement, the Company entered into a registration rights agreement (the “Registration Rights Agreement”), pursuant to which, among other things, the Company prepared and filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S- 1 20% 13 144 not 1933, not may not Except with respect to transactions which may no one may not one 2. During the nine September 30, 2021 2020, 401 During the nine September 30, 2020, 2019

Note 12 - Stock Warrants

Note 12 - Stock Warrants	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Stock Warrants Disclosure [Text Block]	12. Stock Warrants As of September 30, 2021,

Note 13 - Income Taxes

Note 13 - Income Taxes	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. Income Taxes Income taxes are accounted for under the asset and liability method in accordance with Accounting Standards Codification 740, Income Taxes Current accounting standards require a valuation allowance against DTAs if, based on the weight of available evidence, it is more likely than not may not September 30, 2021 December 31, 2020. In assessing the realizability of DTAs, management considers whether it is more likely than not not not not September 30, 2021. Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result, no liability for uncertain tax positions was recorded as of September 30, 2021 December 31, 2020 not twelve September 30, 2021, 2017 2020 As of September 30, 2021, 2021 2040.

Note 14 - Segments

Note 14 - Segments	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	14. Segments We report information about our operating segments using the “management approach” in accordance with current accounting standards. This information is based on the way management organizes and reports the segments within the enterprise for making operating decisions and assessing performance. Our reportable segments are identified based on differences in products, services and markets served. There were no inter-segment sales. We manage our business based on two Tc99m The information in the following tables is derived directly from each reportable segment’s financial reporting. Three Months Ended September 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 9,116 $ — $ — $ 9,116 Grant and other revenue 87,266 — — 87,266 Total revenue 96,382 — — 96,382 Research and development expenses 906,677 142,109 — 1,048,786 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 744 1,450,565 1,451,309 Depreciation and amortization (2) 6,040 — 12,026 18,066 Loss from operations (3) (816,335 ) (142,853 ) (1,462,591 ) (2,421,779 ) Other expense (4) — — (14 ) (14 ) Income tax expense (5,763 ) (824 ) (9,457 ) (16,043 ) Net loss (822,098 ) (143,677 ) (1,472,062 ) (2,437,836 ) Total assets, net of depreciation and amortization: United States $ 185,205 $ — $ 8,557,398 $ 8,742,603 International 216,353 — 590 216,943 Capital expenditures — — 18,042 18,042 Three Months Ended September 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 2,047 $ — $ — $ 2,047 License revenue 4,726 — — 4,726 Grant and other revenue 106,729 154,887 — 261,616 Total revenue 113,502 154,887 — 268,389 Cost of revenue 82 — — 82 Research and development expenses 1,251,383 126,615 — 1,377,998 Selling, general and administrative expenses, excluding depreciation and amortization (1) — — 1,773,532 1,773,532 Depreciation and amortization (2) 4,027 — 11,375 15,402 (Loss) income from operations (3) (1,268,605 ) 28,272 (1,784,907 ) (2,898,625 ) Other expense (4) — — (713 ) (713 ) Net (loss) income (1,141,990 ) 28,272 (1,785,620 ) (2,899,338 ) Total assets, net of depreciation and amortization: United States $ 1,000 $ 38,320 $ 5,839,733 $ 5,879,053 International 116,782 — — 116,782 Capital expenditures 120,810 — — 120,810 Nine Months Ended September 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 44,665 $ — $ — $ 44,665 Grant and other revenue 436,500 — — 436,500 Total revenue 481,165 — — 481,165 Research and development expenses 3,359,190 410,406 — 3,769,596 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,623 5,073,435 5,077,058 Depreciation and amortization (2) 18,121 — 37,551 55,672 Loss from operations (3) (2,896,146 ) (414,029 ) (5,110,986 ) (8,421,161 ) Other income (4) — — 358,436 358,436 Income tax expense (5,763 ) (824 ) (9,457 ) (16,043 ) Net loss (2,901,909 ) (414,853 ) (4,762,007 ) (8,078,768 ) Total assets, net of depreciation and amortization: United States $ 185,205 $ — $ 8,557,398 $ 8,742,603 International 216,353 — 590 216,943 Capital expenditures — — 20,749 20,749 Nine Months Ended September 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 26,188 $ — $ — $ 26,188 License revenue 4,726 — — 4,726 Grant and other revenue 381,103 283,745 — 664,848 Total revenue 412,017 283,745 — 695,762 Cost of revenue 1,048 — — 1,048 Research and development expenses 3,402,160 256,886 — 3,659,046 Selling, general and administrative expenses, excluding depreciation and amortization (1) — (550 ) 4,895,328 4,894,778 Depreciation and amortization (2) 4,027 — 47,474 51,501 (Loss) income from operations (3) (2,995,218 ) 27,409 (4,942,802 ) (7,910,611 ) Other income (4) — — 12,045 12,045 Net (loss) income (2,995,218 ) 27,409 (4,930,757 ) (7,898,566 ) Total assets, net of depreciation and amortization: United States $ 1,000 $ 38,320 $ 5,839,733 $ 5,879,053 International 116,782 — — 116,782 Capital expenditures 120,810 — 8,406 129,216 ( 1 General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not ( 2 Depreciation and amortization are reflected in selling, general and administrative expenses ($18,066 and $15,402 for the three September 30, 2021 2020, nine September 30, 2021 2020, ( 3 Loss from operations does not ( 4 Amounts consist primarily of interest income and interest expense, which are not

Note 15 - Supplemental Disclosu

Note 15 - Supplemental Disclosure for Statements of Cash Flows	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Cash Flow, Supplemental Disclosures [Text Block]	15. Supplemental Disclosure for Statements of Cash Flows During the nine September 30, 2021 2020, nine September 30, 2021, 10 December 31, 2020 December 31, 2020. February 2020, nine September 30, 2021 2020, 401 nine September 30, 2020, 2019 nine September 30, 2020, nine September 30, 2020, nine September 30, 2020,

Note 16 - Subsequent Events

Note 16 - Subsequent Events	9 Months Ended
	Sep. 30, 2021
Notes to Financial Statements
Subsequent Events [Text Block]	16. Subsequent Events The Company has evaluated events and transactions subsequent to September 30, 2021 10 Resignation of CEO: October 24, 2021, The Company’s Board of Directors has established an Executive Leadership Committee to lead the Company on an interim basis while its next CEO is identified. The Executive Leadership Committee includes Michael Rosol, Ph.D., the Company’s Senior Vice President and Chief Medical Officer; Erika Eves, the Company’s Vice President of Finance and Administration; and Jeffrey Smith, the Company’s Vice President of Operations. The Executive Leadership Committee will work with a newly established Board Oversight Committee, consisting of independent directors Alexander Cappello, Thomas Farb and John K. Scott, Jr.

Significant Accounting Policies

Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	a. Basis of Presentation: September 30, 2021 three nine September 30, 2021 2020 September 30, 2021 not December 31, 2020, 10 Our condensed consolidated financial statements include the accounts of Navidea and our wholly owned subsidiaries, Navidea Biopharmaceuticals Europe Limited (“Navidea Europe”) and Navidea Biopharmaceuticals Limited (“Navidea UK”), as well as those of our majority-owned subsidiary, Macrophage Therapeutics, Inc. (“MT”). All significant inter-company accounts were eliminated in consolidation.
Fair Value of Financial Instruments, Policy [Policy Text Block]	b. Financial Instruments and Fair Value: ( 1 Cash and cash equivalents, stock subscriptions and other receivables, and accounts payable: ( 2 Notes payable: September 30, 2021 December 31, 2020 September 30, 2021 December 31, 2020, 8.
Revenue [Policy Text Block]	c. Revenue Recognition: We also earn revenues related to our licensing and distribution agreements. The consideration we are eligible to receive under our licensing and distribution agreements typically includes upfront payments, reimbursement for research and development costs, milestone payments, and royalties. Each licensing and distribution agreement is unique and requires separate assessment in accordance with current accounting standards. See Note 3.
Lessee, Leases [Policy Text Block]	d. Leases: 2018. 12 not 9.
Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	e. Convertible Preferred Stock: 480, Distinguishing Liabilities from Equity 815, Derivatives and Hedging 470, Debt 268, Presentation in Financial Statements of Redeemable Preferred Stocks not not No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity January 1, 2021, not not 11.
New Accounting Pronouncements, Policy [Policy Text Block]	f. Recently Adopted Accounting Standards: December 2019, No. 2019 12, Income Taxes (Topic 740 2019 12 2019 12 740 2019 12 December 12, 2020, 2019 12 not In August 2020, No. 2020 06, Accounting for Convertible Instruments and Contracts in an Entity s Own Equity 2020 06 2020 06 2020 06 2020 06 December 15, 2021, December 15, 2023 2020 06 January 1, 2021 2020 06 not g. Recently Issued Accounting Standards: May 2021, No. 2021 04, Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options 2021 04 ASU2 021 04 ASU2021 04 2021 04 December 15, 2021, not 2021 04

Note 3 - Revenue From Contrac_2

Note 3 - Revenue From Contracts With Customers (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Disaggregation of Revenue [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Royalty revenue: Tc99m tilmanocept - Europe $ — $ 2,047 $ — $ 26,188 License revenue: Tc99m tilmanocept - Europe $ 9,116 $ 4,726 $ 44,665 $ 4,726
Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]	Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Total deferred revenue, beginning of period $ 700,000 $ 860,000 $ 700,000 $ 700,000 Revenue deferred related to sublicense — — — 160,000 Refund of deferred revenue related to sublicense — (160,000 ) — (160,000 ) Revenue recognized from satisfaction of performance obligations — — — — Total deferred revenue, end of period $ 700,000 $ 700,000 $ 700,000 $ 700,000

Note 4 - Stock-based Compensa_2

Note 4 - Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Nine Months Ended September 30, 2021 Number of Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in years) Aggregate Intrinsic Value Outstanding, January 1, 2021 549,970 $ 8.81 8.0 $ 209,280 Granted 234,500 2.53 Exercised (2,000 ) 1.06 Cancelled/Forfeited (67,600 ) 4.01 Expired (2,090 ) 61.75 Outstanding, September 30, 2021 712,780 $ 7.07 7.6 $ 128,765 Exercisable, September 30, 2021 222,882 $ 13.27 5.6 $ 47,381
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Nine Months Ended September 30, 2021 Number of Shares Weighted Average Grant-Date Fair Value Unvested, January 1, 2021 60,000 $ 2.90 Granted 15,000 2.17 Vested (36,667 ) 2.40 Unvested, September 30, 2021 38,333 $ 3.10

Note 6 - Inventory (Tables)

Note 6 - Inventory (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Inventory, Current [Table Text Block]	September 30, 2021 December 31, 2020 Materials $ 77,750 $ 77,750 Finished goods 101,185 92,048 Total inventory $ 178,935 $ 169,798

Note 9 - Leases (Tables)

Note 9 - Leases (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturity of Lease Liabilities Operating Lease Payments 2021 (remaining) $ 93,889 2022 291,111 2023 19,699 2024 1,355 Total undiscounted operating lease payments 406,054 Less imputed interest 25,531 Present value of operating lease liabilities $ 380,523
Lessee, Operating Lease, Assets and Liabilities [Table Text Block]	Balance Sheet Classification Current lease liabilities $ 351,487 Noncurrent lease liabilities 29,036 Total operating lease liabilities $ 380,523
Lease, Cost [Table Text Block]	Other Information Weighted-average remaining lease term for operating leases (in years) 1.1 Weighted-average discount rate for operating leases 11.0 %

Note 14 - Segments (Tables)

Note 14 - Segments (Tables)	9 Months Ended
	Sep. 30, 2021
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Three Months Ended September 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 9,116 $ — $ — $ 9,116 Grant and other revenue 87,266 — — 87,266 Total revenue 96,382 — — 96,382 Research and development expenses 906,677 142,109 — 1,048,786 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 744 1,450,565 1,451,309 Depreciation and amortization (2) 6,040 — 12,026 18,066 Loss from operations (3) (816,335 ) (142,853 ) (1,462,591 ) (2,421,779 ) Other expense (4) — — (14 ) (14 ) Income tax expense (5,763 ) (824 ) (9,457 ) (16,043 ) Net loss (822,098 ) (143,677 ) (1,472,062 ) (2,437,836 ) Total assets, net of depreciation and amortization: United States $ 185,205 $ — $ 8,557,398 $ 8,742,603 International 216,353 — 590 216,943 Capital expenditures — — 18,042 18,042 Three Months Ended September 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 2,047 $ — $ — $ 2,047 License revenue 4,726 — — 4,726 Grant and other revenue 106,729 154,887 — 261,616 Total revenue 113,502 154,887 — 268,389 Cost of revenue 82 — — 82 Research and development expenses 1,251,383 126,615 — 1,377,998 Selling, general and administrative expenses, excluding depreciation and amortization (1) — — 1,773,532 1,773,532 Depreciation and amortization (2) 4,027 — 11,375 15,402 (Loss) income from operations (3) (1,268,605 ) 28,272 (1,784,907 ) (2,898,625 ) Other expense (4) — — (713 ) (713 ) Net (loss) income (1,141,990 ) 28,272 (1,785,620 ) (2,899,338 ) Total assets, net of depreciation and amortization: United States $ 1,000 $ 38,320 $ 5,839,733 $ 5,879,053 International 116,782 — — 116,782 Capital expenditures 120,810 — — 120,810 Nine Months Ended September 30, 2021 Diagnostics Therapeutics Corporate Total License revenue $ 44,665 $ — $ — $ 44,665 Grant and other revenue 436,500 — — 436,500 Total revenue 481,165 — — 481,165 Research and development expenses 3,359,190 410,406 — 3,769,596 Selling, general and administrative expenses, excluding depreciation and amortization (1) — 3,623 5,073,435 5,077,058 Depreciation and amortization (2) 18,121 — 37,551 55,672 Loss from operations (3) (2,896,146 ) (414,029 ) (5,110,986 ) (8,421,161 ) Other income (4) — — 358,436 358,436 Income tax expense (5,763 ) (824 ) (9,457 ) (16,043 ) Net loss (2,901,909 ) (414,853 ) (4,762,007 ) (8,078,768 ) Total assets, net of depreciation and amortization: United States $ 185,205 $ — $ 8,557,398 $ 8,742,603 International 216,353 — 590 216,943 Capital expenditures — — 20,749 20,749 Nine Months Ended September 30, 2020 Diagnostics Therapeutics Corporate Total Royalty revenue $ 26,188 $ — $ — $ 26,188 License revenue 4,726 — — 4,726 Grant and other revenue 381,103 283,745 — 664,848 Total revenue 412,017 283,745 — 695,762 Cost of revenue 1,048 — — 1,048 Research and development expenses 3,402,160 256,886 — 3,659,046 Selling, general and administrative expenses, excluding depreciation and amortization (1) — (550 ) 4,895,328 4,894,778 Depreciation and amortization (2) 4,027 — 47,474 51,501 (Loss) income from operations (3) (2,995,218 ) 27,409 (4,942,802 ) (7,910,611 ) Other income (4) — — 12,045 12,045 Net (loss) income (2,995,218 ) 27,409 (4,930,757 ) (7,898,566 ) Total assets, net of depreciation and amortization: United States $ 1,000 $ 38,320 $ 5,839,733 $ 5,879,053 International 116,782 — — 116,782 Capital expenditures 120,810 — 8,406 129,216

Note 1 - Summary of Significa_2

Note 1 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Notes Payable, Fair Value Disclosure	$ 0	$ 745,000

Note 2 - Liquidity (Details Tex

Note 2 - Liquidity (Details Textual) - USD ($)	Nov. 12, 2021	Jul. 08, 2021	Mar. 02, 2021	Feb. 23, 2021	Aug. 31, 2020	May 18, 2020	Nov. 12, 2021	Dec. 31, 2019	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jul. 08, 2021	Dec. 31, 2019	Aug. 31, 2201	Dec. 31, 2020	Aug. 30, 2020
Common Stock, Par or Stated Value Per Share (in dollars per share)									$ 0.001					$ 0.001					$ 0.001
Proceeds from Issuance of Common Stock								$ 1,900,000						$ 2,135	$ 4,417,560		$ 1,100,000
Stock Issued During Period, Shares, New Issues (in shares)								2,100,000
Stock Issued During Period, Value, New Issues										$ 1,800,000
Stock Subscriptions and Other Receivables									$ 108,323					108,323					$ 2,987,319
Proceeds from Notes Payable, Total														0	366,000
Gain (Loss) on Extinguishment of Debt, Total									0			$ 0		$ 366,000	$ 0
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total						$ 366,000
Gain (Loss) on Extinguishment of Debt, Total				$ 366,000
Series D Preferred Stock [Member]
Stock Issued During Period, Value, New Issues									$ 0		$ 250,001	132,091
Stock Subscriptions and Other Receivables																		$ 0
Preferred Stock, Shares Outstanding, Ending Balance (in shares)									22,077					22,077					0
Series E Preferred Stock [Member]
Stock Issued During Period, Value, New Issues											$ 4,980,709
Preferred Stock, Shares Outstanding, Ending Balance (in shares)									50,000					50,000					0
Subsequent Event [Member] | Series D Preferred Stock [Member]
Preferred Stock, Shares Outstanding, Ending Balance (in shares)	22,077						22,077
Subsequent Event [Member] | Series E Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)	0
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)		22,077			150,000									76,827		72,500
Stock Issued During Period, Value, New Issues		$ 2,200,000			$ 15,000,000									$ 7,700,000		$ 7,250,000
Stock Purchase Agreement, Shares Remaining (in shares)									77,500					77,500
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | Maximum [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)					5,147,000														5,147,000
John K. Scott, Jr. [Member] | Series E Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			50,000
Stock Issued During Period, Value, New Issues			$ 5,000,000
Preferred Stock, Convertible, Shares Issuable (in shares)			2,173,913
Private Placement [Member]
Stock Issued During Period, Value, New Issues												$ 0	$ 520,030
Private Placement [Member] | Mastiff Group LLC [Member]
Sale of Stock, Commitment Amount										$ 4,975,000									$ 4,975,000	$ 25,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)																				$ 0.001
Private Placement [Member] | Mastiff Group LLC [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock	$ 25,000						$ 25,000

Note 3 - Revenue From Contrac_3

Note 3 - Revenue From Contracts With Customers (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Contract with Customer, Payment Term, Minimum (Day)			15 days
Contract with Customer, Payment Term, Maximum (Day)			90 days
Contract with Customer, Transaction Price of Royalties Using Expected Value Method	$ 0		$ 0
Revenue from Contract with Customer, Including Assessed Tax	9,000	$ 7,000	45,000	$ 31,000
Contract with Customer, Asset, Impairment Loss	0	0	0	0
Capitalized Contract Cost, Net, Total	0		0
Contract with Customer, Asset, after Allowance for Credit Loss, Total	107,000		107,000		$ 59,000
Grant [Member]
Revenue from Contract with Customer, Including Assessed Tax		$ 262,000	$ 87,000	$ 665,000
Revenue Not from Contract with Customer	$ 12,000
INDIA
Contract with Customer, Term of Contract (Year)			8 years
CHINA
Contract with Customer, Term of Contract (Year)			10 years

Note 3 - Revenue From Contrac_4

Note 3 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue from contract with customer	$ 9,000	$ 7,000	$ 45,000	$ 31,000
Royalty [Member]
Revenue from contract with customer	0	2,047	0	26,188
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer		2,047		26,188
Diagnostics Segment [Member] | Royalty [Member] | Europe [Member]
Revenue from contract with customer	0	2,047	0	26,188
Diagnostics Segment [Member] | Expanded Tc99m Tilmanocept License Agreement [Member] | Europe [Member]
Revenue from contract with customer	$ 9,116	$ 4,726	$ 44,665	$ 4,726

Note 3 - Revenue From Contrac_5

Note 3 - Revenue From Contracts With Customers - Changes in Contract Liabilities (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Total deferred revenue, beginning of period	$ 700,000	$ 860,000	$ 700,000	$ 700,000
Revenue deferred related to sublicense	0	0	0	160,000
Refund of deferred revenue related to sublicense	0	(160,000)	0	(160,000)
Revenue recognized from satisfaction of performance obligations	0	0	0	0
Total deferred revenue, end of period	$ 700,000	$ 700,000	$ 700,000	$ 700,000

Note 4 - Stock-based Compensa_3

Note 4 - Stock-based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Share-based Payment Arrangement, Expense	$ 108,000	$ 63,000	$ 372,000	$ 136,000
Share-based Payment Arrangement, Expense, Tax Benefit	0	$ 0	$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)			$ 1.86
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum			90.34%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate			0.67%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)			5 years 11 months 19 days
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total	$ 333,000		$ 333,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)			1 year 4 months 24 days

Note 4 - Stock-based Compensa_4

Note 4 - Stock-based Compensation - Summary of Stock Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Outstanding at beginning of period (in shares)	549,970
Outstanding at beginning of period, weighted average exercise price (in dollars per share)	$ 8.81
Outstanding, weighted average remaining contractual life (Year)	7 years 7 months 6 days	8 years
Outstanding, aggregate intrinsic value	$ 128,765	$ 209,280
Granted (in shares)	234,500
Granted, weighted average exercise price (in dollars per share)	$ 2.53
Exercised (in shares)	(2,000)
Exercised, weighted average exercise price (in dollars per share)	$ 1.06
Cancelled/Forfeited (in shares)	(67,600)
Cancelled/Forfeited, weighted average exercise price (in dollars per share)	$ 4.01
Expired (in shares)	(2,090)
Expired, weighted average exercise price (in dollars per share)	$ 61.75
Outstanding at end of period (in shares)	712,780	549,970
Outstanding at end of period, weighted average exercise price (in dollars per share)	$ 7.07	$ 8.81
Exercisable at end of period (in shares)	222,882
Exercisable at end of period, weighted average exercise price (in dollars per share)	$ 13.27
Exercisable, weighted average remaining contractual life (Year)	5 years 7 months 6 days
Exercisable, aggregate intrinsic value	$ 47,381

Note 4 - Stock-based Compensa_5

Note 4 - Stock-based Compensation - Summary of Unvested Restricted Stock (Details) - Restricted Stock [Member]	9 Months Ended
	Sep. 30, 2021$ / sharesshares
Unvested at beginning of period (in shares) | shares	60,000
Unvested at beginning of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.90
Granted (in shares) | shares	15,000
Granted, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.17
Vested (in shares) | shares	(36,667)
Vested, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 2.40
Unvested at end of period (in shares) | shares	38,333
Unvested at end of period, weighted average grant-date fair value (in dollars per share) | $ / shares	$ 3.10

Note 5 - Loss Per Share (Detail

Note 5 - Loss Per Share (Details Textual) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Stock Options and Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	1,685,104	1,521,844
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)	38,333	60,000

Note 6 - Inventory (Details Tex

Note 6 - Inventory (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021
Finished Goods [Member]
Inventory, Allocated to Research and Development Expense	$ 0	$ 10,000

Note 6 - Inventory - Net Invent

Note 6 - Inventory - Net Inventory (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Materials	$ 77,750	$ 77,750
Finished goods	101,185	92,048
Total inventory	$ 178,935	$ 169,798

Note 7 - Accounts Payable, Ac_2

Note 7 - Accounts Payable, Accrued Liabilities and Other (Details Textual) - Director Fees [Member] - USD ($)	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Related Party Transaction, Percentage of Cash payments	50.00%
Related Party Transaction, Percentage of Stock Payments	50.00%
Accounts Payable [Member]
Due to Related Parties, Current, Total	$ 43,000	$ 66,000
Related Party Transaction, Percentage of Related Party Transaction	50.00%
Accrued Liabilities and Other [Member]
Due to Related Parties, Current, Total	$ 792,000	$ 755,000
Related Party Transaction, Percentage of Related Party Transaction	50.00%

Note 8 - Notes Payable (Details

Note 8 - Notes Payable (Details Textual) - USD ($)	Feb. 23, 2021	May 18, 2020	Nov. 30, 2020	Nov. 30, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Interest Expense, Debt, Total					$ 0	$ 0	$ 4,000	$ 5,000
Notes Payable, Current, Total					0		0		$ 745,443
Proceeds from Notes Payable, Total							0	366,000
Gain (Loss) on Extinguishment of Debt, Total					0	0	366,000	0
Notes Payable Issued for Prepayment of Insurance Premiums [Member] | FIF [Member]
Debt Instrument, Face Amount			$ 442,000	$ 349,000
Debt Instrument, Interest Rate, Stated Percentage			3.50%	5.00%
Debt Instrument, Term (Month)			7 months	8 months
Debt Instrument, Periodic Payment, Total			$ 64,000	$ 44,000
Interest Expense, Debt, Total					0	$ 0	4,000	$ 5,000
Notes Payable, Current, Total					$ 0		$ 0		$ 379,000
Paycheck Protection Program CARES Act [Member]
Proceeds from Notes Payable, Total		$ 366,000
Gain (Loss) on Extinguishment of Debt, Total	$ 366,000

Note 9 - Leases (Details Textua

Note 9 - Leases (Details Textual)	1 Months Ended	3 Months Ended		9 Months Ended
	Jun. 30, 2017USD ($)	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)ft²	Sep. 30, 2020USD ($)
Operating Lease, Expense		$ 42,000	$ 49,000	$ 131,000	$ 151,000
Operating Lease, Payments				$ 251,000	$ 246,000
Office Space at 4995 Bradenton Avenue, Dublin Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²		5,000		5,000
Operating Lease, Monthly Base Rent				$ 3,000
Office Space at 5600 Blazer Parkway, Dublin, Ohio [Member]
Area of Real Estate Property (Square Foot) | ft²		25,000		25,000
Operating Lease, Monthly Base Rent	$ 39,000			$ 27,000
Lessee, Operating Lease, Renewal Term (Year)		5 years		5 years
Vehicle Lease [Member]
Operating Lease, Monthly Base Rent				$ 100
Office Equipment [Member]
Operating Lease, Monthly Base Rent				$ 300

Note 9 - Leases - Maturity of L

Note 9 - Leases - Maturity of Lease Liabilities (Details)	Sep. 30, 2021USD ($)
2021 (remaining)	$ 93,889
2022	291,111
2023	19,699
2024	1,355
Total undiscounted operating lease payments	406,054
Less imputed interest	25,531
Present value of operating lease liabilities	$ 380,523

Note 9 - Leases - Balance Sheet

Note 9 - Leases - Balance Sheet Classification (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current lease liabilities	$ 351,487	$ 294,951
Noncurrent lease liabilities	29,036	$ 296,006
Present value of operating lease liabilities	380,523
Other Current Liabilities [Member]
Current lease liabilities	351,487
Other Noncurrent Liabilities [Member]
Noncurrent lease liabilities	$ 29,036

Note 9 - Leases - Other Informa

Note 9 - Leases - Other Information (Details)	Sep. 30, 2021
Weighted-average remaining lease term for operating leases (in years) (Year)	1 year 1 month 6 days
Weighted-average discount rate for operating leases	11.00%

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies (Details Textual) - USD ($)

Jun. 23, 2021

May 27, 2021

Mar. 16, 2021

Nov. 02, 2017

Sep. 30, 2021

Jun. 30, 2021

Mar. 31, 2021

Dec. 31, 2020

Sep. 30, 2020

Jun. 30, 2020

Mar. 31, 2020

Dec. 31, 2019

Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance

$ 4,133,994

$ 6,436,170

$ 5,008,882

$ 2,046,907

$ 901,181

$ (1,622,715)

$ (1,091,039)

$ (880,989)

Market Capitalization, Fair Value

$ 52,800,000

Ohio Court of Common Pleas [Member]

Litigation Settlement, Reversal of Amount Awarded from Other Party

$ 4,300,000

Platinum-Montaur Life Sciences LLC Litigation [Member] | Pending Litigation [Member]

Loss Contingency, Damages Sought, Value

$ 1,900,000

New York Litigation Involving Former CEO and President [Member] | Judicial Ruling [Member]

Litigation Settlement, Amount Can Be Awarded to Other Party for Indemnification for Attorneys’ Fees

$ 14,955

Litigation Settlement, Amount Can Be Advanced to Other Party for Attorneys’ Fees Subject to Repayment

$ 1,237.50

Delaware Litigation Involving Former CEO and President [Member] | Judicial Ruling [Member]

Loss Contingency, Damages Sought, Value

$ 70,000

Note 11 - Equity (Details Textu

Note 11 - Equity (Details Textual) - USD ($)	Nov. 12, 2021	Jul. 08, 2021	Mar. 02, 2021	Aug. 31, 2020	Nov. 12, 2021	Feb. 29, 2020	Dec. 31, 2019	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Jul. 08, 2021	Dec. 31, 2020	Dec. 31, 2019	Aug. 30, 2020
Stock Issued During Period, Shares, New Issues (in shares)							2,100,000
Proceeds from Issuance of Common Stock							$ 1,900,000							$ 2,135	$ 4,417,560			$ 1,100,000
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable								$ 0						0			$ 4,975,000
Stock Issued During Period, Value, New Issues									$ 1,800,000
Proceeds from Issuance of Preferred Stock and Preference Stock														$ 12,682,700	$ 4,350,000
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)														30,018	32,651
Stock Issued During Period, Value, Employee Benefit Plan										$ 76,846		$ 39,834		$ 77,000	$ 40,000
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution														$ 76,846	$ 39,834
Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)									0
Stock Issued During Period, Value, New Issues									$ 0
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)										30,018
Stock Issued During Period, Value, Employee Benefit Plan										$ 30
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)												40,844
Conversion from Series D Preferred Stock To Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)														72,500
Stock Purchase Agreement, Shares Remaining (in shares)								77,500						77,500
Conversion of Stock, Shares Converted (in shares)															1,500
Conversion of Stock, Shares Issued (in shares)															56,497
Series D Preferred Stock [Member]
Stock Issued During Period, Value, New Issues								$ 0		250,001	$ 132,091
Series D Preferred Stock [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)								0			0
Stock Issued During Period, Value, New Issues								$ 0			$ 0
Series E Preferred Stock [Member]
Stock Issued During Period, Value, New Issues										$ 4,980,709
Preferred Stock, Convertible, Conversion Price (in dollars per share)			$ 2.30
Preferred Stock, Redemption Price Per Share (in dollars per share)			$ 110
Subsequent Event [Member] | Conversion from Series D Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)					72,500
Conversion of Stock, Shares Issued (in shares)					3,778,789
Subsequent Event [Member] | Series E Preferred Stock [Member]
Conversion of Stock, Shares Converted (in shares)	0
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)		22,077		150,000										76,827		72,500
Stock Issued During Period, Value, Other				$ 15,000,000
Stock Issued During Period, Value, New Issues		$ 2,200,000		$ 15,000,000										$ 7,700,000		$ 7,250,000
Stock Purchase Agreement, Shares Remaining (in shares)								77,500						77,500
Proceeds from Issuance of Preferred Stock and Preference Stock		$ 9,500,000												$ 2,925,000			$ 2,925,000
Keystone Capital Partners, LLC [Member] | Series D Preferred Stock [Member] | Maximum [Member]
Convertible Preferred Stock, Shares Issued upon Conversion (in shares)				5,147,000													5,147,000
John K. Scott, Jr. [Member] | Series E Preferred Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)			50,000
Stock Issued During Period, Value, New Issues			$ 5,000,000
Percentage of Securities Allowed to be Purchased in Third-Party Offering, Maximum			33.33%
Private Placement [Member]
Stock Issued During Period, Value, New Issues											$ 0	$ 520,030
Private Placement [Member] | Common Stock [Member]
Stock Issued During Period, Shares, New Issues (in shares)											461,729	1,911,800	902,162
Stock Issued During Period, Value, New Issues											$ 462	$ 1,912
Private Placement [Member] | Mastiff Group LLC [Member]
Sale of Stock, Commitment Amount									$ 4,975,000								$ 4,975,000		$ 25,000,000
Private Placement [Member] | Mastiff Group LLC [Member] | Subsequent Event [Member]
Proceeds from Issuance of Common Stock	$ 25,000				$ 25,000
Investor [Member]
Stock Issued During Period, Shares, New Issues (in shares)						4,000,000											4,020,588
Proceeds from Issuance of Common Stock						$ 3,400,000											$ 3,400,000
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)															94,159
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution															$ 172,000
Prepaid Expenses and Other Current Assets [Member]
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable							$ 812,000											$ 812,000

Note 12 - Stock Warrants (Detai

Note 12 - Stock Warrants (Details Textual)	Sep. 30, 2021$ / sharesshares
Class of Warrant or Right, Outstanding (in shares) | shares	972,324
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 17.97
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 0.20
Warrants and Rights Outstanding, Term (Year)	5 years
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 49.80
Warrants and Rights Outstanding, Term (Year)	13 years 10 months 24 days

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Unrecognized Tax Benefits, Ending Balance	$ 0	$ 0
Domestic Tax Authority [Member]
Operating Loss Carryforwards, Total	$ 153,300
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Open Tax Year	2017 2018 2019 2020
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward, Amount	$ 8,900
State and Local Jurisdiction [Member]
Open Tax Year	2017 2018 2019 2020
Operating Loss Carryforwards, Total	$ 20,100

Note 14 - Segments (Details Tex

Note 14 - Segments (Details Textual)		3 Months Ended		9 Months Ended
		Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)	Sep. 30, 2020USD ($)
Revenues, Total		$ 96,382	$ 268,389	$ 481,165	$ 695,762
Number of Primary Types of Products Sold		2		2
Depreciation, Depletion and Amortization, Nonproduction, Total	[1]	$ 18,066	$ 15,402	$ 55,672	$ 51,501
Intersegment Eliminations [Member]
Revenues, Total				$ 0
[1]	Depreciation and amortization are reflected in selling, general and administrative expenses ($18,066 and $15,402 for the three-month periods ended September 30, 2021 and 2020, and $55,672 and $51,501 for the nine-month periods ended September 30, 2021 and 2020, respectively).

Note 14 - Segments - Segment In

Note 14 - Segments - Segment Information (Details) - USD ($)		3 Months Ended								9 Months Ended
		Sep. 30, 2021		Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020		Jun. 30, 2020	Mar. 31, 2020	Sep. 30, 2021		Sep. 30, 2020		Dec. 31, 2020
Revenue from contract with customer		$ 9,000				$ 7,000				$ 45,000		$ 31,000
Grant and other revenue		87,266				261,616				436,500		664,848
Revenues, Total		96,382				268,389				481,165		695,762
Research and development expenses		1,048,786				1,377,998				3,769,596		3,659,046
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,451,309				1,773,532				5,077,058		4,894,778
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	18,066				15,402				55,672		51,501
Loss from operations		(2,421,779)	[3]			(2,898,625)	[3]			(8,421,161)	[3]	(7,910,611)
Other expense (4)	[4]	(14)				(713)
Income tax expense		(16,043)				0				(16,043)		0
Net loss		(2,437,836)		$ (2,674,040)	$ (2,966,892)	(2,899,338)		$ (2,325,619)	$ (2,673,608)	(8,078,768)		(7,898,566)
Total assets, net of depreciation and amortization		8,959,546								8,959,546				$ 7,758,018
Capital expenditures		18,042				120,810				20,749		129,216
Cost of revenue		0				82				0		1,048
Other income (4)		(14)				(713)				358,436	[4]	12,045	[4]
UNITED STATES
Total assets, net of depreciation and amortization		8,742,603				5,879,053				8,742,603		5,879,053
Non-US [Member]
Total assets, net of depreciation and amortization		216,943				116,782				216,943		116,782
License [Member]
Revenue from contract with customer		9,116				4,726				44,665		4,726
Royalty [Member]
Revenue from contract with customer		0				2,047				0		26,188
Diagnostics Segment [Member]
Grant and other revenue		87,266				106,729				436,500		381,103
Revenues, Total		96,382				113,502				481,165		412,017
Research and development expenses		906,677				1,251,383				3,359,190		3,402,160
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	0				0				0		0
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	6,040				4,027				18,121		4,027
Loss from operations		(816,335)	[3]			(1,268,605)	[3]			(2,896,146)	[3]	(2,995,218)
Other expense (4)	[4]	0				0
Income tax expense		(5,763)								(5,763)
Net loss		(822,098)				(1,141,990)				(2,901,909)		(2,995,218)
Capital expenditures		0				120,810				0		120,810
Cost of revenue						82						1,048
Other income (4)	[4]									0		0
Diagnostics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		185,205				1,000				185,205		1,000
Diagnostics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		216,353				116,782				216,353		116,782
Diagnostics Segment [Member] | License [Member]
Revenue from contract with customer		9,116				4,726				44,665		4,726
Diagnostics Segment [Member] | Royalty [Member]
Revenue from contract with customer						2,047						26,188
Therapeutics Segment [Member]
Grant and other revenue		0				154,887				0		283,745
Revenues, Total		0				154,887				0		283,745
Research and development expenses		142,109				126,615				410,406		256,886
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	744				0				3,623		(550)
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	0				0				0		0
Loss from operations		(142,853)	[3]			28,272	[3]			(414,029)	[3]	27,409
Other expense (4)	[4]	0				0
Income tax expense		(824)								(824)
Net loss		(143,677)				28,272				(414,853)		27,409
Capital expenditures		0				0				0		0
Cost of revenue						0						0
Other income (4)	[4]									0		0
Therapeutics Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		0				38,320				0		38,320
Therapeutics Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		0				0				0		0
Therapeutics Segment [Member] | License [Member]
Revenue from contract with customer		0				0				0		0
Therapeutics Segment [Member] | Royalty [Member]
Revenue from contract with customer						0						0
Corporate Segment [Member]
Grant and other revenue		0				0				0		0
Revenues, Total		0				0				0		0
Research and development expenses		0				0				0		0
Selling, general and administrative expenses, excluding depreciation and amortization	[1]	1,450,565				1,773,532				5,073,435		4,895,328
Depreciation, Depletion and Amortization, Nonproduction, Total	[2]	12,026				11,375				37,551		47,474
Loss from operations		(1,462,591)	[3]			(1,784,907)	[3]			(5,110,986)	[3]	(4,942,802)
Other expense (4)	[4]	(14)				(713)
Income tax expense		(9,457)								(9,457)
Net loss		(1,472,062)				(1,785,620)				(4,762,007)		(4,930,757)
Capital expenditures		18,042				0				20,749		8,406
Cost of revenue						0						0
Other income (4)	[4]									358,436		12,045
Corporate Segment [Member] | UNITED STATES
Total assets, net of depreciation and amortization		8,557,398				5,839,733				8,557,398		5,839,733
Corporate Segment [Member] | Non-US [Member]
Total assets, net of depreciation and amortization		590				0				590		0
Corporate Segment [Member] | License [Member]
Revenue from contract with customer		$ 0				0				$ 0		0
Corporate Segment [Member] | Royalty [Member]
Revenue from contract with customer						$ 0						$ 0
[1]	General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[2]	Depreciation and amortization are reflected in selling, general and administrative expenses ($18,066 and $15,402 for the three-month periods ended September 30, 2021 and 2020, and $55,672 and $51,501 for the nine-month periods ended September 30, 2021 and 2020, respectively).
[3]	Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by Navidea Europe, Navidea UK and MT.
[4]	Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.

Note 15 - Supplemental Disclo_2

Note 15 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)	Jul. 08, 2021	Feb. 29, 2020	Mar. 31, 2021	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Interest Paid, Excluding Capitalized Interest, Operating Activities					$ 7,000	$ 5,000
Proceeds from Issuance of Preferred Stock and Preference Stock					$ 12,682,700	$ 4,350,000
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)					30,018	32,651
Stock Issued During Period, Value, Employee Benefit Plan			$ 76,846	$ 39,834	$ 77,000	$ 40,000
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution					76,846	$ 39,834
Conversion from Series C Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)						420,000
Conversion of Stock, Shares Issued (in shares)						1,425,076
Conversion from Series D Preferred Stock To Common Stock [Member]
Conversion of Stock, Shares Converted (in shares)						1,500
Conversion of Stock, Shares Issued (in shares)						56,497
Series OO Warrants [Member]
Class of Warrant or Right, Exercised During Period (in shares)						411,000
Issued Stock Upon Exercise of Warrants, Shares (in shares)						300,595
Common Stock [Member]
Stock Issued During Period, Shares, Employee Benefit Plan (in shares)			30,018
Stock Issued During Period, Value, Employee Benefit Plan			$ 30
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)				40,844
Employees [Member] | Common Stock [Member]
Stock Issued During Period, Shares, Issued for Employee Bonuses (in shares)						94,159
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution						$ 172,000
Office Lease [Member]
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability		$ 100,432
Series D Preferred Stock [Member]
Preferred Stock, Deemed Dividend						17,000
Series D Preferred Stock [Member] | Keystone Capital Partners, LLC [Member]
Proceeds from Issuance of Preferred Stock and Preference Stock	$ 9,500,000				$ 2,925,000		$ 2,925,000
Series C Preferred Stock [Member]
Preferred Stock, Deemed Dividend						$ 467,000